免疫检查点抑制剂在膀胱癌治疗中的研究现状与展望  

Research status and prospects of immune checkpoint inhibitors in the treatment of blad⁃der cancer

作　　者：杨天军 庞磊[1] 问晓东 YANG Tianjun;PANG Lei;WEN Xiaodong(Department of Urology,the Fifth Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China)

机构地区：[1]山西医科大学附属第五临床医学院泌尿外科,山西太原030001

出　　处：《现代肿瘤医学》2023年第4期763-769,共7页Journal of Modern Oncology

基　　金：复旦大学教育部/卫健委/医科院医学分子病毒学重点实验室2021年度开放课题(编号:FDMV-2021004)。

摘　　要：近年来,免疫治疗的迅速发展改变了肿瘤治疗的格局,成为继手术和放化疗之后新的抗肿瘤手段。免疫检查点抑制剂作为目前临床研究最广泛、效果最佳的免疫治疗方法,在膀胱癌的治疗中表现出了良好的抗肿瘤活性和安全性。随着临床试验的不断开展,免疫检查点抑制剂在晚期或转移性膀胱癌的二线治疗乃至一线治疗、肌层浸润性膀胱癌的新辅助和辅助治疗、高危非肌层浸润性膀胱的治疗和保留膀胱的综合治疗中都表现出了极大的治疗潜力。本文重点对免疫检查点抑制剂在各期膀胱癌中的研究进展作综述。In recent years,the rapid development of immunotherapy has changed the pattern of tumor therapy and be⁃come a new anti-tumor method after surgery,radiotherapy and chemotherapy.As the most widely studied and effec⁃tive immunotherapy at present,ICI have shown good anti-tumor activity and safety in the treatment of bladder canc⁃er.With the continuous development of clinical trials,immune checkpoint inhibitors(ICI)show great therapeutic po⁃tential in second-line or first-line treatment of advanced or metastatic bladder cancer,neoadjuvant and adjuvant therapy of muscular invasive bladder cancer,high-risk non-muscular invasive bladder and bladder preservation therapy of muscle invasive bladder cancer.This article briefly reviews the progress of ICI in different stages of bladder cancer.

关 键 词：膀胱癌 免疫治疗 免疫检查点抑制剂 肌层浸润性膀胱癌 

分 类 号：R737.14[医药卫生—肿瘤]